Vection Technologies (ASX:VR1): Fairdinkum or just a fad?
Nick Sundich, March 9, 2023
Vection Technologies (ASX:VR1) is one of the few ASX stocks involved in Virtual Reality (VR).
As a result, its share price has been volatile over the years as investors wonder whether it is fairdinkum or just a fad. A trading update today might suggest it is the former, even if it is only at an early stage.
Who is Vection Technologies?
Vection Technologies has a suite of VR products aimed at businesses. Its most popular, Mindesk, helps businesses render designs in realtime VR.
The company listed on the ASX in April 2019 through a reverse takeover of ServTech, which had listed in 2016.
Its share price has been volatile ever since, going through spikes driven by individual client wins and even non-binding MoUs (Memorandums of Understanding).
The company’s finest moment was in 4Q20 when it won the Italian government as a client, to develop a remote maintenance solution for trains.
An intriguing week
Vection Technologies told shareholders this morning that its Total Contract Value (TCV) was ~$14m, 40% higher than it announced barely a month ago.
It also told shareholders the next two quarters would deliver strong uplift head of $24-$26m in revenue guidance. The company credited sales growth, both from new and existing customers.
It has announced several new contracts of late, most recently a ~$1m order from a top ten defence contractor – announced last Thursday.
Ultimately, we do think Vection Technologies is a fairdinkum business, although it is still not cash flow positive.
So even though it had 10 quarters of cash left as of its last quarterly cash flow report (issued in late December), longer-term investors might not be confident to gamble on this one (yet).
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
NZX companies on the ASX: Here are 4 peculiar ASX stocks you probably didn’t know were NZX listed too
There are roughly 60 NZX companies on the ASX, equating to more than a third of the total number of…
Is a February rate cut from the RBA back on the table? There is hope
Mortgage holders hopefully of a February rate cut are a little more hopeful than they were a week ago, but…
Here’s why Proteomics (ASX:PIQ) shareholders should brace themselves for a big 2025!
Proteomics (ASX:PIQ) is one of the healthcare stocks to watch in CY25, because it has not one, not two, but…